All In Biotech

Drug Trial Radar · NCT06281756

Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia

Cognitive Behavioral Therapy and Trazodone Effects on Sleep and Blood Pressure in Insomnia Phenotypes Based on Objective Sleep Duration: A Sequential Cohort/Randomized Controlled Trial

Last checked: Nov 19, 2026Latest source record: Nov 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Mar 20, 2024

Primary completion

Nov 30, 2027

Study completion May 31, 2028

Sponsor

Lead sponsor
Milton S. Hershey Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Feb 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Individuals who have insomnia with short sleep duration (ISS) differ from individuals who have insomnia with normal sleep duration (INS) in terms of health risks (i.e., hypertension) and treatment response. This study will examine whether patients with ISS and INS demonstrate a differential response to two common insomnia treatments. One is behavioral, Cognitive Behavioral Therapy for Insomnia (CBT-I). The other is a widely prescribed, non-habit-forming medication, trazodone used at a low dose. The investigators' findings could lead to evidence-based treatment guidelines that help clinicians more effectively match treatments to insomnia patients and reduce associated health problems.

Conditions

  • Insomnia
  • Insomnia Chronic
  • Insomnia, Primary
  • Blood Pressure
  • Blood Pressure, High

Interventions

  • Cognitive Behavioral Treatment for Insomnia (CBT-I)Behavioral

    Subjects will receive therapy for 8 weeks

  • TrazodoneDrug

    Non-remitting subjects will receive Trazodone (dosage) for 8 weeks

  • PlaceboOther

    Non-remitting subjects will receive placebo for 8 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Remission of insomnia symptoms following Cognitive Behavioral Therapy for Insomnia (CBT-I)Time frame: 9 weeks
  2. Remission of insomnia symptoms following trazodone/placebo Randomized Controlled Trial (RCT)Time frame: 9 weeks
  3. Remission of insomnia symptoms 6 months following completion of CBT-I Or RCT TreatmentTime frame: 35 weeks

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • National Jewish Health

    Denver, Colorado · Recruiting

  • Penn State University

    Hershey, Pennsylvania · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Université Laval

    Québec, Quebec, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.